Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 9NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Neoplasms 67Lymphoma 55Multiple Myeloma 54Breast Neoplasms 52Neoplasm Metastasis 47Lung Neoplasms 47Prostatic Neoplasms 46Ovarian Neoplasms 39Leukemia, Myeloid, Acute 39Melanoma 37Carcinoma, Non-Small-Cell Lung 37Hematologic Neoplasms 35Colorectal Neoplasms 33Pancreatic Neoplasms 29Glioma 28Lymphoma, Non-Hodgkin 26Urinary Bladder Neoplasms 25Sarcoma 25Carcinoma, Renal Cell 25Brain Neoplasms 24Myelodysplastic Syndromes 21Neuroblastoma 20Triple Negative Breast Neoplasms 19Fallopian Tube Neoplasms 19Stomach Neoplasms 18Leukemia, Lymphocytic, Chronic, B-Cell 18Small Cell Lung Carcinoma 17Colonic Neoplasms 17Burkitt Lymphoma 17Squamous Cell Carcinoma of Head and Neck 16

Interventions

sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Meningeal Neoplasms × 90 days × Clear all
NCT04250545 2026-05-26

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
22 enrolled 14 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡